Dean's Executive Forum Speaker
Martin Marciniak (BS 1991)
VP, U.S. Medical Affairs, Customer Engagement, Value, Evidence, and Outcomes
Martin Marciniak is Vice President, US Medical Affairs responsible for Customer Engagement, Value, Evidence, and Outcomes within GlaxoSmithKline. In this role, he leads the Field Medical Affairs team and the Health Outcomes organization in the generation and communication of evidence for U.S. payers, networked provider organizations, and healthcare providers. In addition, he informs the dialog concerning medical and health policy issues at both a national and local level.
With 17 years of both global and medical affairs experience in the pharmaceutical industry, Dr. Martin’s leadership and research experience has included specific therapeutic area focus in oncology, neuroscience, cardiovascular disease, and policy and economics. He has over 20 publications in peer-reviewed journals and has been invited to present clinical, health outcomes, and economic results at both national and international meetings. In addition to his research activities, Dr. Martin has previously served as a member of the National Quality Forum Cost and Relative Resource Use Steering Committee as a nonvoting industry representative to the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) for the Centers for Medicare and Medicaid Services and as a board member for the National Pharmaceutical Council (NPC) Board of Directors. Presently, he serves on the Editorial Advisory Board for Value and Outcomes Spotlight (an ISPOR publication), and on the advisory board for the Institute for Clinical and Economic Review (ICER). In addition to these activities, he has also served the broader healthcare community in a number of different ways, most recently through invitations to engage in public forum discussions at BioCentury TV and the FDA/CMS Summit.
Dr. Martin has an extensive academic career which includes scientific and public policy research, as well as the strategic management and tactical implementation of observational research programs. He holds a position of Adjunct Assistant Professor in the Division of Pharmaceutical Outcomes and Policy at the University of North Carolina’s Eshelman School of Pharmacy. He received his PhD from the University of California at Berkeley, his master’s degree in Public Policy from Harvard University, and his BS in Pharmacy from Purdue University.